Junichi Hirahashi, MD, PhD; Airi Jo, MD; Kohei Ueda, MD; Akihiro Tojo, MD, PhD; Toshiro Fujita, MD, PhD
Acknowledgment: The authors thank Makoto Arita and Keiichi Hishikawa for pharmacologic assistance; Masaomi Nangaku and George Seki for supervision and critical reading of the manuscript; and Ai Furuta for a vigorous clinical practice.
Grant Support: This work was supported in part by grants from the Ministry of Health, Labour and Welfare of Japan.
Potential Conflicts of Interest: The authors have applied for patents for the use of EPA to treat ANCA-associated vasculitis.
Hirahashi J., Jo A., Ueda K., Tojo A., Fujita T.; Successful Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Eicosapentaenoic Acid. Ann Intern Med. 2012;156:755-756. doi: 10.7326/0003-4819-156-10-201205150-00023
Download citation file:
Published: Ann Intern Med. 2012;156(10):755-756.
Background: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a life-threatening autoimmune disease that often causes inflammatory lesions in the kidneys and lungs. The current standard treatment combines steroids and cyclophosphamide to induce and maintain remission, but this treatment frequently causes adverse events that limit its efficacy (1).
Objective: To successfully induce remission of ANCA-associated vasculitis with an alternative treatment by using eicosapentaenoic acid (EPA) without steroids or immunosuppressants.
Case Report: An 80-year-old woman with aortic stenosis severe enough to cause syncope 1 year earlier presented with rapidly declining renal function. Her history included angina pectoris and myocardial infarction, and she was taking low-dose aspirin, 100 mg/d, to prevent further cardiac events.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only